Somewhat Positive Press Coverage Somewhat Unlikely to Impact BioMarin Pharmaceutical (BMRN) Share Price
Media stories about BioMarin Pharmaceutical (NASDAQ:BMRN) have been trending somewhat positive this week, Accern Sentiment reports. Accern identifies negative and positive press coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. BioMarin Pharmaceutical earned a news impact score of 0.11 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.2538855290489 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
- Are You Looking For Active Stock? BioMarin Pharmaceutical Inc. (BMRN) (nysedaily.com)
- Important Analyst’s Ratings to watch: BioMarin Pharmaceutical Inc. (BMRN) (talktraders.com)
- Stifel’s Thoughts From BioMarin Pharma (BMRN) Management Dinner (streetinsider.com)
- Analysts’ Expectations for Tesaro and Its Peers in August (finance.yahoo.com)
- Here’s What Tesaro’s Valuation Trend Indicates (finance.yahoo.com)
BMRN has been the subject of several recent research reports. JPMorgan Chase & Co. increased their price target on shares of BioMarin Pharmaceutical from $127.00 to $133.00 and gave the stock an “overweight” rating in a research report on Thursday, May 31st. Zacks Investment Research lowered shares of BioMarin Pharmaceutical from a “buy” rating to a “hold” rating in a research report on Wednesday, April 25th. Credit Suisse Group increased their price target on shares of BioMarin Pharmaceutical from $120.00 to $122.00 and gave the stock an “outperform” rating in a research report on Monday, July 9th. Citigroup increased their price target on shares of BioMarin Pharmaceutical to $108.00 and gave the stock a “buy” rating in a research report on Tuesday, May 29th. Finally, BidaskClub lowered shares of BioMarin Pharmaceutical from a “sell” rating to a “strong sell” rating in a research report on Tuesday, April 24th. One equities research analyst has rated the stock with a sell rating, five have given a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has an average rating of “Buy” and a consensus price target of $116.28.
BioMarin Pharmaceutical (NASDAQ:BMRN) last posted its quarterly earnings data on Thursday, August 2nd. The biotechnology company reported ($0.09) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.03). The firm had revenue of $372.80 million for the quarter, compared to analyst estimates of $359.25 million. BioMarin Pharmaceutical had a negative return on equity of 3.00% and a negative net margin of 8.68%. The business’s quarterly revenue was up 17.4% on a year-over-year basis. During the same period in the previous year, the business posted ($0.21) EPS. equities analysts predict that BioMarin Pharmaceutical will post -0.24 earnings per share for the current year.
In other news, EVP Jeffrey Robert Ajer sold 1,436 shares of the stock in a transaction that occurred on Monday, June 11th. The shares were sold at an average price of $90.31, for a total transaction of $129,685.16. Following the sale, the executive vice president now directly owns 50,135 shares of the company’s stock, valued at $4,527,691.85. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Henry J. Fuchs sold 31,000 shares of the stock in a transaction that occurred on Thursday, June 14th. The shares were sold at an average price of $90.00, for a total transaction of $2,790,000.00. Following the sale, the insider now directly owns 157,167 shares in the company, valued at $14,145,030. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 65,874 shares of company stock valued at $6,259,566. Company insiders own 1.90% of the company’s stock.
BioMarin Pharmaceutical Company Profile
BioMarin Pharmaceutical, Inc, a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Aldurazyme that is used for the treatment of patients with mucopolysaccharidosis I, a genetic disease; Brineura for the treatment of late infantile neuronal ceroid lipofuscinosis type 2, a form of Batten disease; and Firdapse for Lambert Eaton Myasthenic Syndrome.
Featured Article: Earnings Per Share
Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.